title: Emerging Therapeutic Options for the Management of COPD.
abstract: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
authors: Department of Pharmacy Practice, School of Pharmacy, Northeastern University, Boston, MA, USA.
authors: Debra J
authors: DJ
authors: Reid
authors: Nga T
authors: NT
authors: Pham
keywords: COPD therapy; chronic obstructive pulmonary disease; long-acting muscarinic agent; long-acting β2-agonist; phosphodiesterase-4 inhibitor
references: Pulm Pharmacol Ther. 2011 Oct;24(5):555-8
references: 21514398
references: Ann Intern Med. 2005 Sep 6;143(5):317-26
references: 16144890
references: Pulm Pharmacol Ther. 2012 Apr;25(2):193-9
references: 22366196
references: Lancet. 2005 Aug 13-19;366(9485):563-71
references: 16099292
references: Lancet. 2009 Aug 29;374(9691):695-703
references: 19716961
references: Respir Res. 2011 Dec 07;12:156
references: 22151296
references: Lancet. 2012 Apr 7;379(9823):1341-51
references: 22314182
references: Am J Med. 2004 Dec 20;117 Suppl 12A:33S-40S
references: 15693641
references: Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94
references: 19265487
references: Lancet. 2009 Aug 29;374(9691):685-94
references: 19716960
references: Respir Res. 2011 Apr 26;12:55
references: 21518460
references: J Pharmacol Exp Ther. 2009 Nov;331(2):740-51
references: 19710368
references: Eur Respir J. 2006 Mar;27(3):547-55
references: 16507855
references: Thorax. 2012 Sep;67(9):781-8
references: 22544891
references: Pulm Pharmacol Ther. 2010 Aug;23(4):235-56
references: 20381629
references: Br J Pharmacol. 2011 May;163(1):53-67
references: 21232047
references: BMC Pulm Med. 2010 Mar 08;10:11
references: 20211002
references: COPD. 2005 Mar;2(1):111-24
references: 17136971
references: Curr Opin Pharmacol. 2012 Jun;12(3):238-45
references: 22445544
references: Pharmacotherapy. 2012 May;32(5):456-74
references: 22499359
references: Pharmacol Rev. 2012 Jul;64(3):450-504
references: 22611179
references: J Pharmacol Exp Ther. 2009 Aug;330(2):660-8
references: 19478135
references: Int J Chron Obstruct Pulmon Dis. 2008;3(2):301-10
references: 18686739
references: Int J Chron Obstruct Pulmon Dis. 2012;7:673-8
references: 23055716
references: Chest. 2012 Nov;142(5):1300-1307
references: 23131938
references: Drug Discov Today. 2012 May;17(9-10):496-504
references: 22119310
references: Int J Chron Obstruct Pulmon Dis. 2008;3(4):543-61
references: 19281073
references: Pulm Pharmacol Ther. 2012 Jun;25(3):248-53
references: 22497752
references: Med Clin North Am. 2012 Jul;96(4):671-80
references: 22793937
references: Drug Des Devel Ther. 2010 Jul 21;4:147-58
references: 20689641
references: Int J Chron Obstruct Pulmon Dis. 2011;6:457-66
references: 22003291
references: Eur Respir J. 2012 Oct;40(4):830-6
references: 22441743
references: Am J Respir Crit Care Med. 2007 Jul 15;176(2):154-61
references: 17463412
references: Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62
references: 20463178
references: Eur Respir J. 2012 Nov;40(5):1106-14
references: 23060624
references: COPD. 2010 Apr;7(2):141-53
references: 20397815
references: COPD. 2012 Apr;9(2):90-101
references: 22320148